Medicine and Dentistry
Heart Failure
100%
Dapagliflozin
82%
Patient
56%
Inpatient
40%
Ejection Fraction
30%
Age
22%
Therapeutic Procedure
20%
Hazard Ratio
20%
Cardiovascular System
18%
Obesity
16%
Heart Left Ventricle Ejection Fraction
15%
Cardiovascular Disease
13%
Atrial Fibrillation
12%
Combination Therapy
11%
Association
11%
Malignant Neoplasm
11%
Maturity Onset Diabetes of the Young
10%
Incidence
10%
Analysis
9%
Chronic Obstructive Pulmonary Disease
9%
Systolic Blood Pressure
9%
Placebo
9%
All Cause Mortality
9%
Amino Terminal Sequence
8%
Deterioration
8%
Evaluation Study
8%
Age Groups
8%
Ketone Body
8%
Mineralocorticoid Antagonist
8%
Multifactorial Disease
8%
Adipose Tissue
8%
Heart Ventricle Arrhythmia
8%
Phospholamban
8%
Body Mass Index
8%
Follow up
7%
Heart Failure with Preserved Ejection Fraction
7%
Heart Failure
7%
Iron Deficiency
7%
Iron
7%
Plasma
7%
Terminal Illness
6%
Adverse Event
6%
Acute Decompensated Heart Failure
6%
Biological Marker
6%
Sex
6%
Event Free Survival
6%
Heart
5%
Kidney
5%
Life
5%
Acetone
5%
Nursing and Health Professions
Heart Failure
47%
Dapagliflozin
41%
Patient
26%
Heart Ejection Fraction
16%
Estimated Glomerular Filtration Rate
15%
Placebo
11%
Atrial Fibrillation
11%
Death
9%
Frailty
8%
Hospitalization
8%
Incidence
7%
Obstructive Lung Disease
7%
Non Insulin Dependent Diabetes Mellitus
7%
Analysis
6%
Time
6%
Event Free Survival
6%
Fat Mass
5%
Inpatient
5%
Follow up
5%
Procedures
5%
Heart Left Ventricle Ejection Fraction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
66%
Dapagliflozin
47%
Placebo
18%
Biological Marker
13%
Heart Failure with Preserved Ejection Fraction
10%
Obesity
10%
Heart Ventricle Arrhythmia
10%
Non Insulin Dependent Diabetes Mellitus
9%
Atrial Fibrillation
8%
Mineralocorticoid Antagonist
8%
Frailty
8%
Hypertrophic Cardiomyopathy
8%
Clinical Trial
8%
Death
8%
Angiotensin
6%
Phospholamban
6%
All Cause Mortality
5%